Newsletter · · Ashutosh Agarwal

Medicare Starts Paying for Obesity Drugs as Local Health Plans Buckle - Healthcare Policy: Drug Pricing, IRA & Managed Care - Week of June 29 to July 4, 2026

CMS switched on the Medicare GLP-1 Bridge Program on July 1, the government's first coverage of obesity drugs for seniors at a negotiated $245, even as Massachusetts towns dropped weight-loss coverage to save jobs and IQVIA data showed GLP-1s are just one point of 2025's 10.6% drug-spend growth. Our synthesis of the healthcare policy podcast tape for the week of June 29 to July 4, 2026.

Healthcare Policy: Drug Pricing, IRA & Managed Care

Week of June 29 to July 4, 2026: Medicare Starts Paying for Obesity Drugs as Local Health Plans Buckle

Intro

The IRA negotiation machinery went quiet this week, no fresh chatter on the 2028 selected-drug list, the pill penalty, or MFN. What filled the vacuum is the story that actually moves P&Ls right now: GLP-1s colliding with public and municipal balance sheets. On July 1, CMS switched on the Medicare GLP-1 Bridge Program, the government's first crack at covering obesity drugs for seniors, and it did so the same week that Massachusetts towns were voting to drop weight-loss coverage to save teacher jobs. That split screen is the whole debate. Below, what the operators and the data people are saying, versus the pundits.

TL;DR

  • Medicare started paying for obesity drugs this week, but through a jury-rigged program that runs outside Part D, sunsets end-2027, and that private plan sponsors already refused to touch voluntarily.
  • The GLP-1 cost panic is real at the plan level but overstated at the system level: GLP-1s are only ~1 point of 2025's 10.6% U.S. drug-spend growth, per IQVIA, the rest is broad, sticky innovation.
  • The read-through risk is migrating from pharma pricing to coverage: 340B rebates, ACA subsidy cliffs, and Medicaid work-reporting are the live wires for hospitals and exchange insurers.

What's new

1. Medicare's obesity coverage arrived, as a workaround, not a policy. On NEJM Interviews (Jun 24), Vanderbilt health-policy professor Stacie Dusetzina (insider/academic) explained that Part D has banned weight-loss coverage since 2003, a relic of the Fen-Phen era. The new Bridge Program "is running completely outside of the Medicare Part D benefit... the government is paying for these drugs separate from the program." Crucially, the more ambitious Balance demonstration was shelved because "Part D plan sponsors... were not interested in participating in this voluntary model." Bridge runs July 1, 2026 through end-2027, uses a clunky deny-then-resubmit claims flow, and, per Dusetzina, awareness is "quite low," pointing to "a really slow start." Why it matters: the plans voting with their feet against voluntary obesity risk tells you exactly how they're modeling the utilization trend.

2. There's a negotiated price, and it's $245. On Off the Chart (Jun 29), the Obesity Action Coalition's Tracy Zvenyach (insider/advocacy) confirmed the administration negotiated GLP-1s to $245, below both retail list and current cash-pay programs, and that the program has now been split: Medicare gets Bridge, while Balance survives only for state Medicaid (voluntary, applications open through July 31). Eligibility is BMI-tiered at 27/30/35. Why it matters: $245 is a low-price, high-volume construct, good for units, thin on margin, and a new anchor point for every payer negotiation that follows.

3. Municipal and employer plans are already breaking. The Journal (Jun 29, WSJ, pundit/reporting) documented a Massachusetts regional insurance trust pushed "on the verge of insolvency," issuing a mid-year surprise assessment. In one town, Duxbury, "7% of its members account for 25% of total pharmacy claims related to GLP-1s prescribed for weight loss alone." Belchertown's trust ultimately eliminated GLP-1 weight-loss coverage (keeping it for diabetes). One town manager is asking employees to choose between a raise and the same health benefits. Why it matters: this is the commercial/self-insured cost curve in miniature, months ahead of the 2027 renewal cycle.

4. The contrarian data point, GLP-1s aren't the whole story. On The Astonishing Healthcare Podcast (Jun 26), IQVIA's Michael Kleinrock (insider/data) put 2025 U.S. drug spend at $606B, up 10.6%, and noted that stripping out GLP-1s and COVID, growth was still 9.6%. "It's only a percentage point of the current growth." The real engine: 28 drugs each grew >$500M, contributing $29.5B of $58B total growth ex-GLP-1, across oncology, immunology, and neurology. He also flagged ~29% of new prescriptions go unfilled, and nearly a million Medicare patients sit above the out-of-pocket cap paying cash. Why it matters: the GLP-1 headline is starving the broader innovation-driven spend story of oxygen, and that broader story is what keeps drug budgets compounding at mid-single-digits through 2030.

The debate: should public payers cover GLP-1s for weight loss?

Cover it (steel-man). You're treating the root cause. As one Massachusetts state-plan advocate put it on The Journal, cutting GLP-1s means "we're cutting off treatment while we keep paying for everything else, the cardiac drugs, the blood pressure medications, the ER visits, hospitalizations." Obesity is a chronic disease; Bridge/Balance finally build a coverage pathway; and a $245 negotiated price makes the math defensible.

Don't (steel-man). The costs are immediate and enormous; the offsets are speculative and decades out. On Actuary Voices (Jun 25), actuary Kimberly Ferrero (insider) noted "some large pharmacy coalitions are reporting that a handful of GLP-1 receptor agonists account for over 20% of total prescription spending," a class scaling faster than actuaries have ever priced, while long-term adherence and durability data remain "very immature." Add gaming risk (patients "exaggerate something," per The Journal) and hard budget crowd-out, and caution is rational. Kleinrock's framing sits underneath both sides: at the system level, GLP-1s are a rounding error on growth, and the panic may be misallocating policy attention.

Read-throughs

  • GLP-1 makers (LLY, NVO): Bridge adds incremental Medicare volume, but at $245 and with a 2027 sunset and slow ramp, it's units over margin. On Everybody's Business (Jun 26, Bloomberg, pundit), reporters noted Lilly (now ~$1T cap) and Novo struck the deal to expand Medicare obesity access, and that Trump said Lilly "wouldn't be subject to tariffs because they were building in the U.S.," a relative competitive positive worth watching if pharma tariffs land.
  • Part D sponsors / managed care (UNH, CVS, HUM, ELV): Their refusal to join Balance voluntarily keeps obesity utilization off their MLR for now, but signals how they view the trend. Bridge sitting outside Part D is a temporary shield, not a solution.
  • Medicaid & exchange insurers (CNC, MOH, ELV): The live risk. On Paging America (Jun 25), a healthcare data analyst (pundit) estimated ACA enrollment losses of 4–5 million this year as enhanced subsidies lapse, with internal federal data reportedly showing >3M dropped by April, and some states (North Carolina) down >20%. Layer on Medicaid work-reporting (live in Nebraska; Arkansas/Montana July 1) and you get a shrinking, adverse-selecting risk pool, a "half death spiral."
  • Hospitals (HCA, THC, UHS): Two-sided. 340B, 16% of all U.S. drug sales, per Telltales (Jul 1, investor panel, pundit), is under attack: Lilly is demanding proof-of-need before paying rebates, and Sen. Cassidy introduced legislation this week to standardize (and arguably tighten) hospital data requirements. Meanwhile coverage losses threaten rural facilities.
  • PBMs / Optum-style services: Kleinrock's most underappreciated point, IRA "price negotiation... lowers the reimbursement price and may remove some of the rebates" that cross-subsidize premiums. Gross-to-net ($1.36T list vs $606B net) is where the value actually sits. Direct-to-consumer channels (TrumpRx, Cost Plus) are a slow disintermediation threat.
  • Biosimilars/generics & ex-US: Biosimilar savings keep getting offset by migration to novel therapies (the Humira/Stelara pattern), and generic GLP-1s remain years off given biologic complexity, so the "savings cliff" the bulls keep waiting for isn't arriving on schedule.

What changed this week

  • Medicare GLP-1 Bridge Program went live July 1; the Medicare arm of Balance was pulled (Medicaid-only now, through 2027).
  • Sen. Cassidy introduced 340B legislation standardizing manufacturer data demands, the first legislative response to Lilly's rebate hardball.
  • Medicaid work-reporting requirements began phasing in (Nebraska live; Arkansas/Montana July 1).